Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañón.
Clin Infect Dis. 2014 Mar;58(5):713-8. doi: 10.1093/cid/cit768. Epub 2013 Nov 21.
Hepatic venous pressure gradient (HVPG) is the best indicator of prognosis in patients with compensated cirrhosis. We compared HVPG and transient elastography (TE) for the prediction of liver-related events (LREs) in patients with hepatitis C virus (HCV)-related cirrhosis with or without human immunodeficiency virus (HIV) coinfection.
This was a retrospective review of all consecutive patients with compensated HCV-related cirrhosis who were assessed simultaneously using TE and HVPG between January 2005 and December 2011. We used receiver operating characteristic (ROC) curves to determine the ability of TE and HVPG to predict the first LRE (liver decompensation or hepatocellular carcinoma).
The study included 60 patients, 36 of whom were coinfected with HIV. After a median follow-up of 42 months, 6 patients died, 8 experienced liver decompensations, and 7 were diagnosed with hepatocellular carcinoma. The area under the ROC curve (AUROC) of TE and HVPG for prediction of LREs in all patients was 0.85 (95% confidence interval [CI], .73-.97) and 0.76 (95% CI, .63-.89) (P = .13); for HIV-infected patients, the AUROC was 0.85 (95% CI, .67-1.00) and 0.81 (95% CI, .64-.97) (P = .57); and for non-HIV-infected patients, the AUROC was 0.88 (95% CI, .75-1.00) and 0.77 (95% CI, .57-.97) (P = .19). Based on the AUROC values, 2 TE cutoff points were chosen to predict the absence (<25 kPa) or presence (≥40 kPa) of LREs, thus enabling correct classification of 82% of patients.
Our data suggest that TE is at least as valid as HVPG for predicting LREs in patients with compensated HCV-related cirrhosis with or without concomitant HIV coinfection.
肝静脉压力梯度(HVPG)是代偿性肝硬化患者预后的最佳指标。我们比较了 HVPG 和瞬时弹性成像(TE)在预测丙型肝炎病毒(HCV)相关肝硬化伴或不伴人类免疫缺陷病毒(HIV)合并感染患者的肝脏相关事件(LRE)中的作用。
这是一项回顾性研究,纳入了 2005 年 1 月至 2011 年 12 月期间同时使用 TE 和 HVPG 评估的所有代偿性 HCV 相关肝硬化连续患者。我们使用接收者操作特征(ROC)曲线来确定 TE 和 HVPG 预测首次 LRE(肝失代偿或肝细胞癌)的能力。
本研究纳入了 60 例患者,其中 36 例合并 HIV 感染。中位随访 42 个月后,有 6 例患者死亡,8 例发生肝失代偿,7 例诊断为肝细胞癌。所有患者的 TE 和 HVPG 预测 LRE 的 ROC 曲线下面积(AUROC)分别为 0.85(95%置信区间 [CI],0.73-0.97)和 0.76(95%CI,0.63-0.89)(P=0.13);在 HIV 感染患者中,AUROC 分别为 0.85(95%CI,0.67-1.00)和 0.81(95%CI,0.64-0.97)(P=0.57);在非 HIV 感染患者中,AUROC 分别为 0.88(95%CI,0.75-1.00)和 0.77(95%CI,0.57-0.97)(P=0.19)。根据 AUROC 值,选择了 2 个 TE 截断值来预测 LRE 的有无(<25 kPa),从而正确分类了 82%的患者。
我们的数据表明,在伴有或不伴有 HIV 合并感染的代偿性 HCV 相关肝硬化患者中,TE 预测 LRE 的有效性至少与 HVPG 相当。